Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody
Selecting the dose for efficacy and first-in-human studies of bispecific antibodies (BsAbs) is a challenging process. Herein, positron emission tomography (PET) imaging with 89Zr-labeled IBI322, an anti-CD47/PD-L1 BsAb, was used to optimize the safety and effective therapy dose. By labeling with 89Z...
Main Authors: | Yan Wang, Donghui Pan, Chenrong Huang, Bingliang Chen, Mingzhu Li, Shuaixiang Zhou, Lizhen Wang, Min Wu, Xinyu Wang, Yicong Bian, Junjie Yan, Junjian Liu, Min Yang, Liyan Miao |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2020.1748322 |
Similar Items
-
89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
by: Albert J. Chang, et al.
Published: (2012-01-01) -
Development of [89Zr]Zr-hCD103.Fab01A and [68Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET
by: Xiaoyu Fan, et al.
Published: (2023-11-01) -
Improved image reconstruction of 89Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm
by: Julian Kirchner, et al.
Published: (2021-01-01) -
The Race for Hydroxamate-Based Zirconium-89 Chelators
by: Irene V. J. Feiner, et al.
Published: (2021-09-01) -
Pretargeting for imaging and therapy in oncological nuclear medicine
by: Clément Bailly, et al.
Published: (2017-06-01)